Cardiovascular Disease in Rheumatoid Arthritis

Rheumatic Disease Clinics of North America

Volumn 40, Issue 1, 2014, Pages 27-49

  Sen, Deepali ^a   González Mayda, María ^a   Brasington, Richard D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Inflammation; Management; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DICLOFENAC; EPITOPE; ETANERCEPT; GLUCOCORTICOID; GOLD; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INFLIXIMAB; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; PREDNISONE; ROFECOXIB; SALAZOSULFAPYRIDINE; SIMVASTATIN; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR;

AGE; ARTERITIS; BIOLOGICAL THERAPY; BODY MASS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEART AMYLOIDOSIS; HEART CATHETERIZATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; MORBIDITY; MORTALITY; MYOCARDIAL DISEASE; PERICARDITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SMOKING; TRANSTHORACIC ECHOCARDIOGRAPHY; VALVULAR HEART DISEASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; INFLAMMATION; MANAGEMENT; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 84888198987     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.10.005     Document Type: Review

References (168)

1. Mutru O., Koota K., Isomäki H. Causes of death in autopsied RA patients. Scand J Rheumatol 1976, 5:239-240.
2. Koivuniemi R., Paimela L., Suomalainen R., et al. Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatol 2013, 42(2):131-135.
3. Kitas G., Banks M., Bacon P. Cardiac involvement in rheumatoid arthritis. Clin Med 2001, 1:18-21.
4. Corrao A., Salli L., Arnone R., et al. Cardiac involvement in rheumatoid arthritis: evidence of silent heart disease. Eur Heart J 1995, 16:253-256.
5. Mody G.M., Stevens J.E., Meyers O.L. The heart in rheumatoid arthritis: a clinical and echocardiographic study. QJ Med 1987, 65:921-928.
6. Barcin C., Yalcinkaya E., Kabul H.K. Cholesterol pericarditis associated with rheumatoid arthritis: a rare cause of pericardial effusion. Int J Cardiol 2013, 166(3):e56-e58.
7. Escalante A., Kaufman R.L., Quismorio F.P., et al. Cardiac compression in rheumatoid pericarditis. Semin Arthritis Rheum 1990, 20(3):148-163.
8. Nyhäll-Wåhlin B.M., Petersson I.F., Jacobsson C., et al. Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors. Scand J Rheumatol 2012, 41:434-437.
9. Ambrose N.L., O'Connell P.G. Anti-TNF alpha therapy does not always protect rheumatoid arthritis patients against developing pericarditis. Clin Exp Rheumatol 2007, 25(4):660.
10. Nagyhegyi G., Nades I., Banyai F., et al. Cardiac and cardiopulmonary disorders in patients with ankylosing spondylitis and rheumatoid arthritis. Clin Exp Rheumatol 1988, 6:17-26.
11. Wisłowska M., Sypuła S., Kowalik I. Echocardiographic findings, 24-hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol 1998, 17(5):369-377.
12. Guedes C., Bianchi-Fior P., Cormier B., et al. Cardiac manifestations of rheumatoid arthritis: a case control transesophageal echocardiography study in 30 patients. Arthritis Care Res 2001, 45:129-135.
13. Roldan C.A., DeLong C., Qualls C.R., et al. Characterization of valvular heart disease in rheumatoid arthritis by transesophageal echocardiography and clinical correlates. Am J Cardiol 2007, 100(3):496-502.
14. Corrao S., Messina S., Pistone G., et al. Heart involvement in rheumatoid arthritis: systematic review and meta-analysis. Int J Cardiol 2013, 167(5):2031-2038.
15. Wisłowska M., Sypuła S., Kowalik I. Echocardiographic findings and 24-h electrocardiographic Holter monitoring in patients with nodular and non-nodular rheumatoid arthritis. Rheumatol Int 1999, 18(5-6):163-169.
16. Yiu K.H., Wang S., Mok M.Y., et al. Relationship between cardiac valvular and arterial calcification in patients with rheumatoid arthritis and systemic lupus erythematosus. JRheumatol 2011, 38(4):621-627.
17. Nicola P.J., Crowson C.S., Maradit-Kremers H., et al. Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 2006, 54:60-67.
18. Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004, 116:305-311.
19. Nicola P.J., Maradit-Kremers H., Roger V.L., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005, 52(2):412-420.
20. Myasoedova E., Crowson C.S., Nicola P.J., et al. The influence of rheumatoid arthritis disease characteristics on heart failure. JRheumatol 2011, 38(8):1601-1606.
21. Mustonen J., Laakso M., Hirvonen T., et al. Abnormalities in left ventricular diastolic function in male patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest 1993, 23:246-253.
22. Crowson C.S., Myasoedova E., Davis J.M., et al. Use of B-type natriuretic peptide as a screening tool for left ventricular diastolic dysfunction in rheumatoid arthritis patients without clinical cardiovascular disease. Arthritis Care Res (Hoboken) 2011, 63:729-734.
23. Corrao S., Sallì L., Arnone S., et al. Echo-Doppler left ventricular filling abnormalities in patients with rheumatoid arthritis without clinically evident cardiovascular disease. Eur J Clin Invest 1996, 26(4):293-297.
24. Rudominer R.L., Roman M.J., Devereux R.B., et al. Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum 2009, 60:22-29.
25. Yazici D., Tokay S., Aydin S., et al. Echocardiographic evaluation of cardiac diastolic function in patients with rheumatoid arthritis: 5 years of follow-up. Clin Rheumatol 2008, 27:647-650.
26. Liang K.P., Myasoedova E., Crowson C.S., et al. Increased prevalence of diastolic dysfunction in rheumatoid arthritis. Ann Rheum Dis 2010, 69(9):1665-1670.
27. Gonzalez-Juanatey C., Testa A., Garcia-Castelo A., et al. Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004, 33(4):231-238.
28. Aslam F., Bandeali S., Khan N., et al. Diastolic dysfunction in rheumatoid arthritis. A meta-analysis and systematic review. Arthritis Care Res 2013, 65:534-543.
29. Correa de Sa D.D., Hodge D.O., Slusser J.P., et al. Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 2010, 96:528-532.
30. Corrao S., Scaglione R., Calvo L., et al. Ameta-analysis of the effect size of rheumatoid arthritis on left ventricular mass: comment on the article by Rudominer etal. Arthritis Rheum 2009, 60(9):2851-2852.
31. Giles J.T., Malayeri A.A., Fernandes V., et al. Left ventricular structure and function in patients with rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging. Arthritis Rheum 2010, 62(4):940-951.
32. Davis J., Knutson K., Strausbauch M., et al. Signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum 2011, 63(6):1497-1506.
33. Giles J.T., Fert-Bober J., Park J.K., et al. Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis Res Ther 2012, 14(1):R39.
34. Costedoat-Chalumeau N., Hulot J.S., Amoura Z., et al. Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 2007, 107(2):73-80.
35. Nord J.E., Shah P.K., Rinaldi R.Z., et al. Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature. Semin Arthritis Rheum 2004, 33:336-351.
36. Cotroneo J., Sleik K.M., Rene Rodriguez E., et al. Hydroxychloroquine-induced restrictive cardiomyopathy. Eur J Echocardiogr 2007, 8:247-251.
37. Manohar V.A., Moder K.G., Edwards W.D., et al. Restrictive cardiomyopathy secondary to hydroxychloroquine therapy. JRheumatol 2009, 36:440-441.
38. Muthukrishnan P., Roukoz H., Grafton G., et al. Hydroxychloroquine-induced cardiomyopathy: a case report. Circ Heart Fail 2011, 4:e7-e8.
39. Newton-Cheh C., Lin A.E., Baggish A.L., et al. Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure. NEngl J Med 2011, 364:1450-1460.
40. Hartmann M., Meek I.L., van Houwelingen G.K., et al. Acute left ventricular failure in a patient with hydroxychloroquine-induced cardiomyopathy. Neth Heart J 2011, 19:482-485.
41. Azimian M., Gultekin S.H., Hata J.L., et al. Fatal antimalarial-induced cardiomyopathy: report of 2 cases. JClin Rheumatol 2012, 18(7):363-366.
42. Joyce E., Fabre A., Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy. Eur Heart J Acute Cardiovasc Care 2013, 2:77.
43. Sumpter M.D., Tatro L.S., Stoecker W.V., et al. Evidence for risk of cardiomyopathy with hydroxychloroquine. Lupus 2012, 21(14):1594-1596.
44. Freihage J.H., Patel N.C., Jacobs W.R., et al. Heart transplantation in a patient withchloroquine-induced cardiomyopathy. JHeart Lung Transplant 2004, 23:252-255.
45. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. NEngl J Med 1990, 323:236-241.
46. Kadokami T., Frye C., Lemster B., et al. Anti-tumor necrosis factor-{alpha} antibody limits heart failure in a transgenic model. Circulation 2001, 104:1094-1097.
47. Li Y.Y., Feng Y.Q., Kadokami T., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci USA 2000, 97:12746-12751.
48. Deswal A., Bozkurt B., Seta Y., et al. Aphase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR: Fc) in patients with advanced heart failure. Circulation 1999, 99:3224-3226.
49. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
50. Chung E.S., Packer M., Lo K.H., Anti-TNF therapy against congestive Heart Failure Investigators, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107(25):3133-3140.
51. Kwon H.J., Cote T.R., Cuffe M.S., et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138:807-811.
52. Jacobsson L.T., Turesson C., Gülfe A., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. JRheumatol 2005, 32:1213-1218.
53. Dixon W.G., Watson K.D., Lunt M., et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912.
54. Carmona L., Descalzo M.A., Perez-Pampin E., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66:880-885.
55. Listing J., Strangfeld A., Kekow J., et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008, 58:667-677.
56. Cole J., Busti A., Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor α antagonists. Rheumatol Int 2007, 27:369-373.
57. Barnabe C., Martin B., Ghali W. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res 2011, 4:522-529.
58. Bely M., Apathy A. Amyloid A deposition in rheumatoid arthritis: a retrospective clinicopathologic study of 161 autopsy patients. Amyloid 2012, 19(4):212-213.
59. Koivuniemi R., Paimela L., Suomalainen R., et al. Amyloidosis is frequently undetected in patients with rheumatoid. Amyloid 2008, 15(4):262-268.
60. El Mansoury T.M., Hazenberg B.P., El Badawy S.A., et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 2002, 61:42-47.
61. Kuroda T., Tanabe N., Sakatsume M., et al. Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rheumatol 2002, 21:123-128.
62. Kuroda T., Tanabe N., Kobayashi D., et al. Treatment with biologic agents improves the prognosis of patients with rheumatoid arthritis and amyloidosis. JRheumatol 2012, 39(7):1348-1354.
63. Kuroda T., Wada Y., Kobayashi D., et al. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosalamyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. JRheumatol 2009, 36(11):2409-2415.
64. Cruickshank B. Heart lesions in rheumatoid disease. JPathol Bacteriol 1958, 76:223-240.
65. Lebowitz W.B. The heart in rheumatoid arthritis: a clinical and pathological study of 62 cases. Ann Intern Med 1963, 58:102-123.
66. van Albada-Kuipers G.A., Bruijn J.A., Westedt M.L., et al. Coronary arteritis complicating rheumatoid arthritis. Ann Rheum Dis 1986, 45(11):963-965.
67. Avina-Zubieta J., Thomas J., Sadatsafavi M., et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012, 71:1524-1529.
68. Douglas K.M., Pace A.V., Treharne G.J., et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis 2006, 65(3):348-353.
69. Van Doornum S., Brand C., King B., et al. Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54(7):2061-2068.
70. Pasceri V., Yeh E.T. Atale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999, 100(21):2124-2126.
71. Myasoedova E., Crowson C.S., Kremers H.M., et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010, 69:1310-1314.
72. Myasoedova E., Crowson C., Kremers H., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011, 70(3):482-487.
73. Hahn B.H., Grossman J., Ansell B.J., et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008, 10(4):213.
74. Charles-Schoeman C., Watanabe J., Lee Y.Y., et al. Abnormal function of high density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009, 60(10):2870-2879.
75. Wada Y., Kuroda T., Murasawa A., et al. Autoantibodies against oxidized low-density lipoprotein (LDL) and carotid atherosclerosis in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005, 23:482-486.
76. Hurt-Camejo E., Paredes S., Masana L., et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001, 44:2761-2767.
77. Dursunoǧlu D., Evrengül H., Polat B., et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005, 25(4):241-245.
78. Park Y.B., Choi H.K., Kim M.Y., et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002, 113:188-193.
79. Boers M., Nurmohamed M.T., Doelman C.J., et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:842-845.
80. Morris S., Wasko M., Antohe J., et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res 2011, 63(4):530-534.
81. van Sijl A.M., Peters M.J., Knol D.L., et al. The effect of TNF-α blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin Arthritis Rheum 2011, 41(3):393-400.
82. Jones G., Sebba A., Gu J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96.
83. Maini R.N., Taylor P.C., Szechinski J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006, 54:2817-2819.
84. Schiff M.H., Kremer J.M., Jahreis A., et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011, 13(5):R141.
85. Weinblatt M.E., Kremer J., Cush J., et al. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care Res 2013, 65(3):362-371.
86. Genovese MC, Sebba A, Rubbert-Roth A, etal. Long-term safety of tocilizumab in rheumatoid arthritis clinical trials. Presented at ACR [abstract 2217]. Chicago, 2011.
87. Fleischmann R., Kremer J., Cush J., et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. NEngl J Med 2012, 367:495-507.
88. van Vollenhoven R.F., Fleischmann R., Cohen S., et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. NEngl J Med 2012, 367:508-519.
89. Burmester G.R., Blanco R., Charles-Schoeman C., et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013, 381(9865):451-460.
90. McCarey D.W., McInnes I.B., Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004, 363:2015-2021.
91. Sheng X., Murphy M.J., Macdonald T.M., et al. Effectiveness of statins on total cholesterol and cardiovascular disease and all-cause mortality in osteoarthritis and rheumatoid arthritis. JRheumatol 2012, 39:32-40.
92. Cojocaru L., Rusali A.C., Suţa C., et al. The role of simvastatin in the therapeutic approach of rheumatoid arthritis. Autoimmune Dis 2013, 2013:326258.
93. Van Doornum S., McColl G., Wicks I.P. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004, 63(12):1571-1575.
94. Hermann F., Forster A., Chenevard R., et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. JAm Coll Cardiol 2005, 45(3):461-464.
95. Maki-Petaja K.M., Booth A.D., Hall F.C., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. JAm Coll Cardiol 2007, 50(9):852-858.
96. De Vera M.A., Choi H., Abrahamowicz M., et al. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011, 70:1020-1024.
97. Panoulas V., Douglas K., Milionis H., et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007, 46:1477-1482.
98. Boyer J.F., Gourraud P.A., Cantagrel A., et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 2012, 78:179-183.
99. Chung C., Giles J., Petri M., et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum 2012, 41:535-544.
100. Han C., Robinson D., Hackett M., et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. JRheumatol 2006, 33:2167-2172.
101. Simard J., Mittleman M. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. JRheumatol 2007, 34:469-473.
102. Solomon D., Curhan G., Rimm E., et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004, 50:3444-3449.
103. La Montagna G., Cacciapuoti F., Buono R., et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. Diab Vasc Dis Res 2007, 4(2):130-135.
104. Chung C.P., Oeser A., Solus J.F., et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2008, 196(2):756-763.
105. Dessein P., Joffe B., Stanwix A. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. JRheumatol 2003, 30(7):1403-1405.
106. Hotamisligil G.S., Arner P., Caro J.F., et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. JClin Invest 1995, 95(5):2409-2415.
107. Kern P.A., Saghizadeh M., Ong J.M., et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. JClin Invest 1995, 95(5):2111-2119.
108. Saghizadeh M., Ong J.M., Garvey W.T., et al. The expression of TNF alpha by human muscle. Relationship to insulin resistance. JClin Invest 1996, 97(4):1111-1116.
109. Hotamisligil G.S., Murray D.L., Choy L.N., et al. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994, 91:4854-4858.
110. Nilsson J., Jovinge S., Niemann A., et al. Relation between plasma tumor necrosis factor-alpha and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998, 18(8):1199-1202.
111. Peters M.J., van Halm V.P., Voskuyl A.E., et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61:1571-1579.
112. Crowson C.S., Therneau T.M., Davis J.M., et al. Brief report: accelerated aging influences cardiovascular disease risk in rheumatoid arthritis. Arthritis Rheum 2013, 65(10):2562-2566.
113. Maradit-Kremers H.M., Nicola P.J., Crowson C.S., et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004, 50(11):3450-3457.
114. George J., Levy Y., Shoenfeld Y. Smoking and immunity: an additional player in the mosaic of autoimmunity. Scand J Immunol 1997, 45:1-6.
115. Costenbader K., Feskanich D., Mandl L., et al. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006, 119:503-509.
116. Saag K., Cerhan J., Kolluri S., et al. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997, 56:463-469.
117. Helmersson J., Larsson A., Vessby B., et al. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 2005, 181:201-207.
118. Gerli R., Sherer Y., Vaudo G., et al. Early atherosclerosis in rheumatoid arthritis: effect of smoking on thickness of the carotid artery intima media. Ann N Y Acad Sci 2005, 1051:281-290.
119. Maradit-Kremers H., Crowson C.S., Therneau T.M., et al. High ten year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients. Arthritis Rheum 2008, 58:2268-2274.
120. Young A., Koduri G., Batley M., et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007, 46:350-357.
121. Goodson N.J., Wiles N.J., Lunt M., et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002, 46:2010-2019.
122. Georgiadis A.N., Voulgari P.V., Argyropoulou M.I., et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 2008, 38:13-19.
123. Hannawi S., Haluska B., Marwick T., et al. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther 2007, 9:R116.
124. Kao A.H., Krishnaswami S., Cunningham A., et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. JRheumatol 2008, 35(1):61-69.
125. Chung C.P., Oeser A., Raggi P., et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005, 52(10):3045-3053.
126. Turesson C., Jacobsson L.T., Sturfelt G., et al. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:59-64.
127. Sihvonen S., Korpela M., Mustila A., et al. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. JRheumatol 2005, 32(11):2089-2094.
128. Gerli R., Bartolini Bocci E., Sherer Y., et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67:724-725.
129. Farragher T.M., Goodson N.J., Naseem H., et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008, 58:359-369.
130. Mattey D.L., Thomson W., Ollier W., et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 2007, 56:1408-1416.
131. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Lopez-Diaz M.J., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:125-132.
132. Goodson N.J., Symmons D.P., Scott D.G., et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005, 52:2293-2299.
133. Graf J., Scherzer R., Grunfeld C., et al. Levels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritis. PLoS One 2009, 4:e6242.
134. Gonzalez-Gay M.A., Gonzalez-Juanatey C., Pineiro A., et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. JRheumatol 2005, 32(7):1219-1223.
135. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006, 83:456S-460S.
136. Fonseca J.E., Santos M.J., Canhão H., et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009, 8:538-542.
137. Schieffer B., Schieffer E., Hilfiker-Kleiner D., et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000, 101:1372-1378.
138. Olopien B., Hyper M., Kowalski J., et al. Anew immunological marker of atherosclerotic injury of arterial wall. Res Commun Mol Pathol Pharmacol 2001, 109:241-248.
139. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. Circulation 2003, 108:2317-2322.
140. Barath P., Fishbein M.C., Cao J., et al. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990, 65:297-302.
141. Schjerning Olsen A.M., Fosbøl E.L., Lindhardsen J., et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011, 123(20):2226-2235.
142. Trelle S., Reichenbach S., Wandel S., et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011, 342:c7086.
143. Hudson M., Baron M., Rahme E., et al. Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction. JRheumatol 2005, 32(8):1589-1593.
144. Goodson N.J., Brookhart A.M., Symmons D.P., et al. Nonsteroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. Ann Rheum Dis 2009, 68:367-372.
145. Lindhardsen J., Gislason G.H., Jacobsen S., et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2013, [Epub ahead of print].
146. Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141:764-770.
147. Greenberg J., Kremer J., Curtis J., et al. Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:576-582.
148. Davis J.M., Maradit Kremers H., Crowson C.S., et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007, 56:820-830.
149. Aviña-Zubieta J.A., Abrahamowicz M., De Vera M.A., et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013, 52(1):68-75.
150. Aviña-Zubieta J.A., Abrahamowicz M., Choi H.K., et al. Risk of cerebrovascular disease associated with the use of glucocorticoids in patients with incident rheumatoid arthritis: a population-based study. Ann Rheum Dis 2011, 70(6):990-995.
151. Crowson C.S., Matteson E.L., Roger V.L., et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol 2012, 110(3):420-424.
152. Peters M.J., Symmons D.P., McCarey D., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
153. Crowson C., Gabriel S. Towards improving cardiovascular risk management in patients with RA: need for a accurate risk assessment. Ann Rheum Dis 2011, 70:719-721.
154. Toms T.E., Panoulas V.F., Douglas K.M., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under treatment of lipid associated cardiovascular risk?. Ann Rheum Dis 2010, 69:683-688.
155. Tikiz C., Utuk O., Pirildar T., et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. JRheumatol 2005, 32:2095-2101.
156. Flammer A.J., Sudano I., Hermann F., et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008, 117:2262-2269.
157. Martin M.F., Surrall K.E., McKenna F., et al. Captopril: a new treatment for rheumatoid arthritis?. Lancet 1984, 1:1325-1328.
158. Choi H.K., Hernan M.A., Seeger J.D., et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177.
159. Westlake S.L., Colebatch A.N., Baird J., et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010, 49:295-307.
160. Micha R., Imamura F., Wyler von Ballmoos M., et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011, 108:1362-1370.
161. El-Barbary A., Kassem E., El-Sergany M.A., et al. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide. JRheumatol 2011, 38(5):828-834.
162. Solomon D.H., Curtis J.R., Saag K.G., et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med 2013, 126(8):730.e9-730.e17.
163. Al-Aly Z., Pan H., Zeringue A., et al. Tumor necrosis factor-alpha blockade, cardiovascular outcomes, and survival in rheumatoid arthritis. Transl Res 2011, 157:10-18.
164. Provan S.A., Semb A.G., Hisdal J., et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011, 70:812-817.
165. Maki-Petaja K.M., Hall F.C., Booth A.D., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006, 114:1185-1192.
166. Galarraga B., Khan F., Kumar P., et al. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1418-1423.
167. Wong M., Oakley S.P., Young L., et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68:1277-1284.
168. Barnabe C., Martin B.J., Ghali W.A. Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011, 63:522-529.